Navigation Links
Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin

PRINCETON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO), a global healthcare company, today released its financial statement for the period January 1, 2007 to September 30, 2007.

-- Novo Nordisk increased sales by 14% in local currencies and by 9% in

Danish kroner due to a significant negative currency development.

-- Sales of modern insulins increased by 37% (31% in Danish kroner).

-- Sales of NovoSeven(R) increased by 10% (4% in Danish kroner).

-- Sales of Norditropin(R) increased by 12% (7% in Danish kroner).

-- Sales in North America increased by 25% (15% in Danish kroner).

-- Gross margin increased to 76.7% in the first nine months of 2007 up

from 75.2% in the same period last year, primarily reflecting continued

productivity improvements.

-- Operating profit increased by 11% to USD 1,410 million. Adjusted for

the impact from currencies, underlying operating profit increased by

more than 20%.

-- Net profit increased by 60% to USD 1,361 million, primarily reflecting

the divestment of Dako's business activities in the second quarter of

2007. Earnings per share (diluted) increased by 62% to USD 4.26.

-- The expectation for full-year sales growth is still 11-14% measured in

local currencies and now 6-9% as reported due to the depreciation of

key invoicing currencies. Full-year operating profit growth remains

unchanged around 20% measured in local currencies and is now expected

to be close to 10% as reported.

-- In October, Novo Nordisk received marketing authorization for

Levemir(R) in Japan for both type 1 and type 2 diabetes including

combination treatment with oral antidiabetics.

Lars Rebien Sorensen, president and CEO, said "Our portfolio of modern insulins continues to show strong sales growth in all key markets. Within the next few months we will be launching Levemir(R) in FlexPen(R) in Japan, which will further support growth in the coming years."

* For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.00 = DKK 5.54317.

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems.In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit

SOURCE Novo Nordisk
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. cMaster RTplusPCR System for increased sensitivity and product length in RT-PCR
2. Increased Sensitivity in Microarray Analysis
3. Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell
4. Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery
5. VC funding increased in third quarter with shining life sciences
6. Wisconsin-based Third Wave reports increased revenue for 2003, fourth quarter
7. Alfalight Gets $3.8M From DARPA - Funding has increased to $8.5 Million
8. Brinkmann/Eppendorf SOP Standard Operating Procedure for Pipettes
9. Sonic Foundry posts explosive growth, though still operating at a loss
10. Fiserv reports $113.5 million in Q1 profit
11. Re-engineering our economy to be sustainable and profitable
Post Your Comments:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... 23, 2016 adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):